Renal Osteodystrophy

Renal osteodystrophy is a specific term used to describe the distinct bone pathology that occurs as a complication of chronic kidney disease (CKD).
It is a core component of the broader systemic condition known as CKD-Mineral and Bone Disorder (CKD-MBD), which encompasses alterations in mineral ion homeostasis, bone turnover, mineralization, volume, linear growth, and cardiovascular disease such as vascular calcification.
The condition is characterized by profound abnormalities in bone turnover (which can be high or low), skeletal mineralization, and bone volume, and it is nearly universal in patients at the start of dialysis therapy.

The pathogenesis of renal osteodystrophy is driven by a complex interplay between the kidneys, gut, bone, and parathyroid glands that disrupts mineral homeostasis as the glomerular filtration rate (GFR) declines.
Circulating fibroblast growth factor 23 (FGF23) levels increase in very early CKD due to decreased renal FGF23 clearance, altered bone biology, and an early decline in renal Klotho, which is a critical FGF23 co-factor.
Elevated FGF23 suppresses renal 1-alpha-hydroxylase activity, causing 1,25-dihydroxyvitamin D (calcitriol) levels to fall, which in turn significantly reduces intestinal calcium absorption.
The combination of low 1,25-dihydroxyvitamin D and low ionized calcium levels stimulates parathyroid hormone (PTH) release from the parathyroid glands, resulting in secondary hyperparathyroidism.
Decreased phosphate excretion due to a critically low renal mass further contributes to hyperphosphatemia, which also continuously stimulates PTH secretion.
Uremia itself alters bone cell biology, contributing to skeletal PTH resistance, impaired osteoblast maturation, and intrinsic mineralization defects.

Type of Osteodystrophy	Characteristics	Pathogenesis & Associations
High-Turnover Bone Disease (Osteitis Fibrosa Cystica)	Increased bone formation rate, increased cellular activity, disorganized bone matrix, and peri-trabecular fibrous changes.	Driven by prolonged secondary hyperparathyroidism and elevated PTH levels; it is the most common bone condition seen in advanced pediatric CKD.
Low-Turnover Bone Disease (Adynamic Bone Disease)	Decreased bone formation rate, decreased cellular activity, highly mineralized bone, and an absence of excessive osteoid accumulation.	Associated with PTH over-suppression, hypercalcemia, and low alkaline phosphatase (ALP) activity; often results from overaggressive therapy with active vitamin D sterols and calcium salts in dialysis patients.
Defective Mineralization (Osteomalacia/Rickets)	Wide osteoid seams, an increased number of osteoid lamellae, and a diminished rate of mineral deposition; fibrosis is characteristically absent.	May occur in early CKD prior to secondary hyperparathyroidism; associated with 25-hydroxyvitamin D deficiency, phosphate depletion, and elevated FGF23.
Mixed Uremic Osteodystrophy	Defective skeletal mineralization combined with simultaneously increased bone formation rates.	Characterized by wide osteoid seams, prolonged mineralization times, bone marrow fibrosis, and increased bone formation rates.

Clinical manifestations include vague and nonspecific symptoms initially, progressing to severe bone pain, muscle weakness, and profound growth retardation.
Children often present with overt bone deformities, including rachitic changes, varus and valgus deformities of the long bones, and slipped capital femoral epiphyses (SCFE).
Pathological fractures can occur with minor trauma due to the severely altered bone quality.
Radiographic evaluation of high-turnover disease typically reveals subperiosteal bone resorption, metaphyseal widening, and osteopenia.

Serum biomarkers should be monitored serially based on the CKD stage and include calcium, phosphorus, PTH, alkaline phosphatase (ALP), and 25-hydroxyvitamin D.
Hypocalcemia, hyperphosphatemia, and elevated levels of ALP and PTH are hallmark biochemical characteristics of the high-turnover state seen in secondary hyperparathyroidism.
In adynamic bone disease, PTH is over-suppressed, commonly accompanied by hypercalcemia and low ALP activity.
Iliac crest bone biopsy with double tetracycline labeling remains the gold standard for diagnosis; it provides definitive information about the histologic appearance and dynamics of bone formation and mineralization.
Severe abnormalities in bone volume and mineralization may be observed on conventional radiographs, which are specifically indicated in children with bone pain, suspected atraumatic fractures, or manifestations suggestive of avascular necrosis.

The primary goals of intervention are to maintain normal bone mineralization and growth, avoid hyperphosphatemia and hypocalcemia, and prevent or reverse increased PTH secretion.
Dietary management involves the restriction of phosphate intake, usually by limiting dairy products, to maintain age-appropriate serum phosphorus values.
Oral phosphate binders, administered with meals, are utilized to reduce intestinal absorption of phosphate.
Calcium-based binders (such as calcium carbonate or acetate) or non-calcium-based binders (such as sevelamer carbonate) can be used, while aluminum hydroxide must be strictly avoided due to the risk of bone disease and encephalopathy.
Nutritional vitamin D deficiency must be corrected using ergocalciferol or cholecalciferol to provide a substrate for 1,25-dihydroxyvitamin D formation and to delay the onset of secondary hyperparathyroidism.
If PTH remains elevated despite the correction of 25-hydroxyvitamin D and hyperphosphatemia, active vitamin D sterols such as calcitriol, paricalcitol, or 1-alpha-hydroxyvitamin D3 are indicated to suppress PTH production and increase intestinal calcium absorption.
Recombinant human growth hormone may be considered for children with significant height deficits, provided that metabolic acidosis and mineral and bone disorders are first addressed.
Surgical intervention, such as osteotomy, may ultimately be required to correct severe bony deformities.